Smoking is considered a serious risk factor for developing a large array of cardiopulmonary conditions, in particular, squamous cell carcinoma in nonsmall cell lung cancer (NSCLC). Smoking cessation has reduced the risk of lung cancers and has benefited cancer patients receiving chemotherapy.
Introduction
Smoking is considered a serious problem that leads to diseases particularly non-small cell lung cancer (NSCLC). 
Smoking Will Not Be Completely Eliminated

For Several Decades
Smoking has a long history. Although considerable effort has been put forth by governments, organizations, and the public, it will not be completely eliminated in the near future. According to the reports from the World Health Organization (WHO) [1] , in 2015, over 1.1 billion people smoked tobacco, which represented about one-seventh of the world population. There are currently more than 300 million smokers in China, nearly one-third of the world's total.
According to DCD reports [2] , an estimated 14.0% of U.S. citizens were cigarette smokers in 2017, representing a 67% decline since 1965. Despite the improvement in rates, 14% still represented a sizeable proportion as it equates to approximately 34 million people. Such a large number is not likely to decline rapidly because until 2019, "only 37 countries, representing 15% of the world's population, have completely banned all forms of tobacco advertising, promotion, and sponsorship" [1] . Therefore, smoking behaviors are not expected to completely cease in the near future. Rather, a large population will continue to do so, especially in lung cancer patients in which smokers represent its majority. As such, drug development that targets smokers may be a valuable approach for lung cancer treatment. 
Examination of Current Clinical Trials
Definitive Conclusions Cannot Be Drawn From
Most Large-Scale Clinical Trials
The relationship between smoking status and treatment response in NSCLC patients resulted in a mixed picture. In the beginning, we started performing a PubMed search on May 10, 2018 by using the keywords "non-small-cell-lungcancer trial III" with the restriction that the studies must be clinical trials performed in humans in the last 10 years. A total of 868 publications were identified. We examined these publications and collected the data from a total of 31 large clinical trials, each of which has at least 100 patients.
Among them, 24 studies, with a total of over 14 thousand patients, compared the HR values of never smokers with ever smokers ( 
Analysis of Treatment Efficacy Should be Based on Individual Drugs
One question that we explored was whether the effect of chemotherapy on smokers was dependent on the specific modality. Considering the complexities in cancer treatment, analyses of individual efficacies in chemotherapeutic treatments for smokers with NSCLC is essential. Perhaps there might be some treatments better suited for patients with a more extensive smoking history. We found in recent reports that the response to treatment by PD-1 and PD-L1 inhibitors were positive in smokers. The last four entries listed in Table 1 (Table 1) . These two drugs belong to the PD-L1 class.
In both trials, the current and former smokers responded to treatment better than non-smokers. It is intriguing that four clinical trials studying chemotherapy efficacy in NSCLC patients based on the same drug class all resulted in lower HR values in smokers. Furthermore, all of these clinical trials tested the efficacy of a single drug and resulted in a statistically significant P-value of 0.048 when comparing smokers to nonsmokers. Thus, there were no confounding factors that would need to be considered such as those in a multi-regimen based chemotherapy. conditions may be the factor in contributing to this "sensitivity". As of now, it is certainly difficult to atrribute a single explanation for chemotherapeutic sensitivity in NSCLC. Food-induced or oral tolerance has been well recognized as well as respiratory immune tolerance in asthma [12] , but pulmonary immunological tolerance in NSCLC is an area that requires further research. Smoking is a major risk factor in developing lung cancer.
However, its potential for inducing chemotherapy sensitivity has not been adequately studied. Other harmful materials or behaviors have been extensively studied and have been implemented in improving health in patients (Table II) . For example, the use of opioids in reducing pain balanced by its respiratory risks [13] . With alcohol, positive cardiovascular effects in moderation balanced by negative neurological consequences in excess [14] have been widely recognized and investigated. In addition, arsenic trioxide's cytotoxic effects were discovered to be useful in cancer treatment [15] . Harmful behaviors have both a relatively positive as well as a well-recognized negative result. Early in this decade, melamine finds its way in adulterated milk [16] . Also, vitamin D is important for bone growth but results in harmful hypercalcemia when in excess [17] . Even running marathons, a nationally recognized sport, has pros and cons [18] . While smoking cessation can improve pulmonary function, perhaps tailoring the use of PD-1 and PD-L1 agents to smokers can result in even better patient outcomes.
There are certainly enormous hurdles in studying smoking- 
